Yousif, W., Al Saadawi, A. (2023). Immunohistochemical Expression of P53 in Urothelial Bladder Lesions in a Sample of Patients. Alustath, 22(3), 307-312. doi: 10.52573/ipmj.2023.181194
Wafaa Gamal Yousif; Adil R. Al Saadawi. "Immunohistochemical Expression of P53 in Urothelial Bladder Lesions in a Sample of Patients". Alustath, 22, 3, 2023, 307-312. doi: 10.52573/ipmj.2023.181194
Yousif, W., Al Saadawi, A. (2023). 'Immunohistochemical Expression of P53 in Urothelial Bladder Lesions in a Sample of Patients', Alustath, 22(3), pp. 307-312. doi: 10.52573/ipmj.2023.181194
Yousif, W., Al Saadawi, A. Immunohistochemical Expression of P53 in Urothelial Bladder Lesions in a Sample of Patients. Alustath, 2023; 22(3): 307-312. doi: 10.52573/ipmj.2023.181194

Immunohistochemical Expression of P53 in Urothelial Bladder Lesions in a Sample of Patients

Iraqi Postgraduate Medical Journal
Article 11, Volume 22, Issue 3, July 2023, Pages 307-312    PDF (343.99 K)
DOI: 10.52573/ipmj.2023.181194
Authors
Wafaa Gamal Yousif* 1; Adil R. Al Saadawi2
1Central Teaching Hospital of Peadiatric, Baghdad, Iraq.
2National Center for Educational Laboratories Baghdad, Iraq
Abstract
BACKGROUND:
TCC is the most common cancer in urinary bladder, despite important advances in cancer treatment, the disease continues to become a big challenges to the clinicians due to high recurrence rate. Invasive urothelial carcinoma is characterized by alterations in cell-cycle regulatory pathways. Altered expression of the TP53 gene has been associated with TCC.
OBJECTIVE:
To evaluate the expression of p53 in urothelial bladder lesions immunohistochemically and to correlate the immunohistochemical expression of p53 with tumor grade and histological diagnosis of lesions.
MATERIALS & METHODS:
This is a retrospective study of 50 bladder biopsy in AL Shaheed Ghazi AL Hariri hospital in Baghdad (covering the period from Jan 2018 to Feb 2019). 49 were transurethral biopsy specimens and 1 was radical cystectomy. Two sections of 5μm thickness were taken from each block, the first was stained (H&E) for histological revision, the other section was stained IHC for TP53.
RESULTS:
The patient’s age was in range of 13 to 89 years with mean of 61.24 years. The highest proportion of study patients was aged > 60 years (70%).
The immunostaining of TP53 was nuclear, P53 positive in 4/10 cases (40%) of flat hyperplasia, 12/19 cases (63.2%) of low grade papillary transitional cell carcinoma and 19/21 cases (90.5%) of high grade papillary transitional cell carcinoma.
CONCLUSION:
There was statistical significant correlation between TP53 expression and urothelial bladder lesions, tumor grade and patients gender.
 
Keywords
TP53; Transitional cell carcinoma; Immunohistochemistry
References
  1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2013;63:234-41.
  2. Yang et al "Expression of cyclin bladder cancer and correlation in cancer progression" 2002; 69:190-94.
  3. Iraq Cancer Board, results of Iraqi Cancer Registry 2011, Ministry of health, Iraq Cancer Registry Centre, Baghdad – Iraq, 2016.
  4. Robins and Cotran "Pathologic Basis of Disease" 2015,Ch21:964 Ninth Edition.
  5. Juan Rosai, Rosai and ackermans surgical pathology. Tenth edition 2011;1:1247-86.
  6. Roychowdhury M Flat hyperplasia. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/bladderflathyperplasia.html. Accessed October 20th, 2019.
  7. Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, Ji Y, Huang LW, Jia HL, Sun HC, Wang L. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World journal of gastroenterology. 2002;8:459.
  8. Tawfeeq KT, Al-Talib SH. P53 over-expression in urothelial carcinoma of the bladder: An Immunohistochemical Study. Medical Journal of Tikrit. 2012;18:189-211.
  9. Mumtaz S, Hashmi AA, Hasan SH, Edhi MM, Khan M. Diagnostic utility of p53 and CK20 immunohistochemical expression grading urothelial malignancies. International archives of medicine. 2014;7:36.
  10. Ali SA, Sadeq B. A study of p53 expression in transitional cell carcinoma of urinary bladder in Erbil governorate. Zanco Journal of Medical Sciences (Zanco J Med Sci). 2012;16:248-55.
  11. Alvaro S Sarkis, Guido Dalbagni, Carlos Cordon-Cardo, Zuo-Feng Zhang, Joel Sheinfeld, William R Fair, Harry W Herr, and Victor E Reuter. Nuclear Overexpression of p53 Protein in TCC of bladder: A Marker for Disease Progression. JNCI Journal of the National Cancer Institute 1993;85:53-59.
  12. Anadi RC, Dey RK. Expression of p53 Protein by Immunohistochemistry in Urothelial Neoplasm: A Hospital-based Study from Eastern India. Int J Sci Stud 2017;5:142-145.
  13. Kalantari M, Ahmadnia H. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification. Urology journal. 2009;4:230-33.
  14. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI.Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasia. Archives of pathology & laboratory medicine. 2001;125:646-51.
Statistics
Article View: 50
PDF Download: 51


Journal Management System. Powered by ejournalplus.com